Paper69552
Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.
Stevenson GT and 2 others. Fed Proc, 1977. Cited by 116 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Papers, record 69552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/69552
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Anti-Idiotypic | Major topic |
| B-Lymphocytes | Major topic |
| Binding Sites, Antibody | Major topic |
| Guinea Pigs | Major topic |
| Immunoglobulin Variable Region | Major topic |
| Leukemia, Experimental | Major topic |
| Leukemia, Lymphoid | Major topic |
| Receptors, Antigen, B-Cell | Major topic |
| Animals | |
| Antigens, Neoplasm | |
| Clone Cells | |
| Epitopes | |
| Humans | |
| Immunoglobulin Allotypes | |
| Immunoglobulin Fab Fragments | |
| Immunoglobulin lambda-Chains | |
| Immunoglobulin mu-Chains | |
| Immunotherapy | |
| Isoantibodies |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00006184 | Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | Background |
Source ClinicalTrials.gov
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 116 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,275,113 | Identification, assembly and characterization of tumor immunoglobulin transcripts from RNA sequencing data using IgSeqR. | Nat Protoc | 2025 | https://conductscience.org/library/papers/40275113 | PubMed |
| 39,128,904 | Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. | Nat Commun | 2024 | https://conductscience.org/library/papers/39128904 | PubMed |
| 37,345,057 | Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345057 | PubMed |
| 29,439,670 | Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. | BMC Cancer | 2018 | https://conductscience.org/library/papers/29439670 | PubMed |
| 25,755,905 | Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes. | Am J Blood Res | 2014 | https://conductscience.org/library/papers/25755905 | PubMed |
| 25,483,639 | Antigen-specific vaccines for cancer treatment. | Hum Vaccin Immunother | 2014 | https://conductscience.org/library/papers/25483639 | PubMed |
| 24,399,190 | Peptide vaccines for hematological malignancies: a missed promise? | Int J Hematol | 2014 | https://conductscience.org/library/papers/24399190 | PubMed |
| 23,264,902 | Trial watch: Peptide vaccines in cancer therapy. | Oncoimmunology | 2012 | https://conductscience.org/library/papers/23264902 | PubMed |
| 21,048,000 | Translating tumor antigens into cancer vaccines. | Clin Vaccine Immunol | 2011 | https://conductscience.org/library/papers/21048000 | PubMed |
| 20,848,095 | Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells. | Cancer Immunol Immunother | 2011 | https://conductscience.org/library/papers/20848095 | PubMed |
| 20,425,407 | Vaccination strategies in follicular lymphoma. | Curr Hematol Malig Rep | 2009 | https://conductscience.org/library/papers/20425407 | PubMed |
| 18,422,783 | Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. | Br J Haematol | 2008 | https://conductscience.org/library/papers/18422783 | PubMed |
| 17,326,239 | Therapeutic vaccine for lymphoma. | Yonsei Med J | 2007 | https://conductscience.org/library/papers/17326239 | PubMed |
| 15,146,248 | Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. | J Clin Invest | 2004 | https://conductscience.org/library/papers/15146248 | PubMed |
| 12,895,388 | Vaccination strategies for lymphomas. | Curr Oncol Rep | 2003 | https://conductscience.org/library/papers/12895388 | PubMed |
| 12,841,382 | Immunotherapy for lymphomas. | Int J Hematol | 2003 | https://conductscience.org/library/papers/12841382 | PubMed |
| 12,612,576 | Immunotherapy: past, present and future. | Nat Med | 2003 | https://conductscience.org/library/papers/12612576 | PubMed |
| 7,192,154 | Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. | Br J Cancer | 1980 | https://conductscience.org/library/papers/7192154 | PubMed |
| 7,049,456 | The assessment of anti-idiopathic antibodies as effective immunoregulatory probes in vivo. | Clin Exp Immunol | 1982 | https://conductscience.org/library/papers/7049456 | PubMed |
| 6,970,174 | Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. I. Characterization with syngeneic and xenogeneic complements. | Immunology | 1981 | https://conductscience.org/library/papers/6970174 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/69552
GET https://conductscience.org/api/papers/v1/69552/cited_by?page=2